Sonoma Pharmaceuticals Inc. (SNOA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sonoma Pharmaceuticals Inc. (SNOA:NASDAQ), powered by AI.

Current Price
$1.14
P/E Ratio
-0.4
Market Cap
1M
Sector
Healthcare
What is the Sonoma Pharmaceuticals Inc. stock price forecast?

Sonoma Pharmaceuticals Inc. is currently trading at $1.14. View real-time AI analysis on Alpha Lenz.

What is Sonoma Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Sonoma Pharmaceuticals Inc. on Alpha Lenz.

What is Sonoma Pharmaceuticals Inc.'s P/E ratio?

Sonoma Pharmaceuticals Inc.'s P/E ratio is -0.4.

Sonoma Pharmaceuticals Inc.

NASDAQ · SNOA
$1.14
Ask about Sonoma Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Sonoma Pharmaceuticals Inc. trades at a P/E of -0.4 (undervalued) with modest ROE of -65.5%.

Ask for details

Company Overview

Sonoma Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing healing solutions for dermatological conditions and advanced wound care. The primary purpose of this entity is to create non-toxic therapies that safely reduce infections and inflammation, accelerating the body's natural healing processes. Its product portfolio includes a range of topical anti-infective treatments and skin care solutions tailored for various fields, including dermatology, wound care, eye care, and animal health. Sonoma's formulations commonly feature hypochlorous acid, an element known for its antimicrobial and soothing properties. Significantly impacting the healthcare and pharmaceutical sectors, Sonoma Pharmaceuticals addresses critical needs in infection management and chronic wound therapy. The company’s innovations are particularly beneficial in hospital settings, outpatient clinics, and home care, offering versatile treatment options for both human and animal patients. Headquartered in Boulder, Colorado, the company's reach extends internationally, underscoring its role as a key player in improving patient outcomes through scientifically-backed therapeutic products.

CEOMs. Amy M. Trombly Esq., J.D.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees8

Company Statistics

FY 2025

Profile

$1.41MMarket Cap
$14.29MRevenue
0.00Shares Out
8Employees

Margins

38.25%Gross
-25.00%EBITDA
-25.97%Operating
-20.35%Pre-Tax
-24.20%Net

Valuation

-0.41P/E
0.32P/B
0.10EV/Sales
1.02EV/EBITDA
-8.42P/FCF

Growth (CAGR)

4.20%Rev 3Yr
-4.44%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-24.32%ROA
-65.55%ROE
-26.10%ROIC

Financial Health

$5.37MCash & Cash Equivalents
$3.91MNet Debt
210.43%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Sonoma Pharmaceuticals Inc. (ticker: SNOA) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 8 employees. Market cap is $1M.

The current price is $1.14 with a P/E ratio of -0.41x and P/B of 0.32x.

ROE is -65.55% and operating margin is -25.97%. Annual revenue is $14M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Sonoma Pharmaceuticals Inc. (Healthcare) Stock Forecast & Analysis $1.14 | Alpha Lenz